Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Bayer’s gene therapy juggling act
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
Apellis takes the complement fight to Astrazeneca
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Kinaset takes a sledgehammer to an asthma conundrum
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Thermo Fisher and the new variant
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
Astra aims for “the Trump setting”
Pivotal trials of Astrazeneca's Covid-19 antibody get under way, with hopes that a longer half-life and more convenient dosing will set the project apart.
The other kind of Covid-19 immunity
As antibody tests pile up, Oxford Immunotec is working on an assay to detect T cell responses to the coronavirus.
Novo adds weight to its obesity goals
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
